PharmTech Drug Digest 11.20
News|Articles|March 8, 2023

Actylis Opens 30,000-square-foot API Manufacturing Facility

Author(s)Grant Playter

Actylis new 30,000-ft² API manufacturing facility is located in Eugene, Ore.

Actylis, a global specialty ingredients manufacturer and supplier, announced the formal opening of its new API manufacturing facility on Feb. 27, 2023. The facility, located in Eugene, Ore., is good manufacturing practice (GMP)-compliant and designed to supply both APIs and excipients at both clinical trial and commercial scale.

“We are excited to have this state-of-the-art facility here in Eugene come on line after such an intensive design and development process,” said Christine Bellmor, site director, in a company press release. “We have [seven] manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3 [third quarter]. We have a number of different reactors to allow flexibility for a variety of chemistries. Commissioning and qualifications for clinical GMP were completed at the end of January this year and we already have our first projects completed, and more are underway.”

“We designed this facility specifically to enable us to develop and produce innovative APIs for our customers,” said Gilles Cottier, CEO, Acylis, in the release. “We worked closely with architect firm BCA (Blaise Cacciola Architect) and Coffman Engineering to build a facility that has the most up-to-date technology and equipment available.”

Source: Actylis


Related to this article

Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.